What question did this study set out to answer?

The aim was to assess the efficacy of autologous lymphokine-activated killer cells and interleukin-2 in patients with metastatic cancer who failed standard therapy.

December 5, 1985New England Journal of Medicine

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

View Full Paper

Ask AI

Bookmark

The aim was to assess the efficacy of autologous lymphokine-activated killer cells and interleukin-2 in patients with metastatic cancer who failed standard therapy.
Evaluated 25 patients with advanced cancer after standard treatments failed.
Administered 1.8 to 18.4 X 10(10) autologous LAK cells and up to 90 doses of interleukin-2.
Monitored for objective regression of cancer and side effects.
Objective regression of cancer was noted in 11 out of 25 patients (44%).
Complete tumor regression occurred in one patient with metastatic melanoma, sustained for 10 months post-therapy.
Severe fluid retention was the main side effect, resolving after stopping interleukin-2.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates tumor regression in metastatic cancer with autologous LAK cells and interleukin-2, suggesting new treatment possibilities.

Cite This Study

Rosenberg et al. (1985) studied this question.

synapsesocial.com/papers/6a0cf465d69d74dc6d0ce5d6 https://doi.org/10.1056/nejm198512053132327

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates tumor regression in metastatic cancer with autologous LAK cells and interleukin-2, suggesting new treatment possibilities.

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Key Points

Discussion

Implication

Cite This Study

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider